Biogen Media |

All Press Releases

Biogen Idec Highlights Progress and Breadth of Pipeline Programs at R&D Day
3/25/09 8:30 am EDT
Biogen Idec Announces March 25 Webcast of Research & Development Day
3/18/09 4:03 pm EDT
Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire
3/12/09 4:01 pm EDT
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
3/11/09 4:30 pm EDT
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
3/10/09 11:05 am EDT
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
2/23/09 4:00 pm EST
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
2/9/09 2:00 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
2/6/09 7:34 am EST
Biogen Idec Receives Shareholder Proposal
2/6/09 7:32 am EST
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
1/9/09 11:51 am EST

Biogen Idec Announces Head of Research and Development Dr. Cecil B. Pickett to Retire
3/12/09 4:01 pm EDT
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
3/11/09 4:30 pm EDT
Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference
3/10/09 11:05 am EDT
Biogen Idec Names Michael Lytton Executive Vice President of Business Development
2/23/09 4:00 pm EST
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
2/9/09 2:00 am EST
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results
2/6/09 7:34 am EST
Biogen Idec Receives Shareholder Proposal
2/6/09 7:32 am EST
Biogen Idec to Report Fourth Quarter and Full Year 2008 Financial Results on February 6, 2009
1/9/09 11:51 am EST
Biogen Idec to Present at the 27th Annual J.P. Morgan Healthcare Conference
1/6/09 12:47 pm EST
Biogen Idec to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
1/5/09 1:49 pm EST